Hologic Inc's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Hologic Inc's ROA in the first quarter of 2026?
Hologic Inc achieved a return on average assets (ROA) of 6.12 % in its first quarter of 2026, this is above HOLX's average return on assets of 3.94%.
Hologic Incs assets during the 12 months ending in the first quarter of 2026 are valued at $8 billion

ROA decreased relative to the period ending Sep 27 2025, due to the decline in net income.

However, within the Healthcare sector 160 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2025 from 955 to 1180.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 27 2025) I. Quarter	(Sep 27 2025) IV. Quarter	(Jun 28 2025) III. Quarter	(Mar 29 2025) II. Quarter	(Dec 28 2024) I. Quarter
Y / Y Total Assets Change	5.15 %	-1.56 %	-0.94 %	-1.94 %	3.09 %
Y / Y Net Income Change	-10.9 %	4.82 %	0.21 %	-	-18.46 %
Net Income (TTM) in million	544	566	557	557	744
Return On Assets (TTM)	6.12 %	6.45 %	6.32 %	6.3 %	8.38 %
HOLX's Total Ranking	# 1180	# 955	# 976	# 982	# 862
Total Assets (TTM) in million	9,181	9,015	8,806	8,545	8,731
Seq. Total Assets Change	1.84 %	2.37 %	3.05 %	-2.13 %	-4.67 %
Seq. Net Income Change	-4.33 %	-3.95 %	-	-	12.54 %

HOLX's 5 Years Annual ROA >> Back to HOLX Management Effectiveness >> Compare HOLX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 7
Sector	# 161
Overall	# 1173

Return On Assets Statistics
High	Average	Low
26.02 %	3.94 %	-13.13 %
(Jun 26 2021)		(Jun 28 2014)

Financial Statements
Hologic Inc's Assets	$ 9,181 million	HOLX's Balance sheet
Hologic Inc's Income	$ 179 million	Quarterly HOLX's Income Statement
HOLX's Income by Division		See HOLX's Income by Division

Annual Return On Assets	(Sep 27 2025) FY 2025	(Sep 28 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 24 2022) FY 2022	(Sep 25 2021) FY 2021
Y / Y Total Assets Change	-1.56 %	0.21 %	0.75 %	1.7 %	23.96 %
Total Assets in million	9,015	9,158	9,139	9,071	8,920
Y / Y Net Income Change	-28.35 %	73.14 %	-64.98 %	-30.36 %	68.37 %
Net Income in million	566	790	456	1,302	1,870
Annual Return On Assets	6.28 %	8.62 %	4.99 %	14.35 %	20.96 %

HOLX's 5 Years Annual ROA >> Back to HOLX Management Effectiveness >> Compare HOLX ROA to its Competitors

Comment on HOLX's ROA in the fiscal year ending 2025

In the fiscal year 2025 Hologic Inc's ROA decreased compared to previous year to 6.28 %, due to deterioration of net income -28.35 % to $565.70 million, from $789.50 million a year ago, as HOLX's assets were $9,014.90 million.

More Return On Assets Ratios
HOLX's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HOLX's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HOLX's Competitors
Subscribers only: Roa for Hologic Inc's Suppliers
Subscribers only: Return On Assets for HOLX's Customers

You may also want to know
HOLX's Roi	HOLX's Inventory Turnover Ratio	HOLX's Growth Rates	HOLX's Dividend Comparisons
	HOLX's Profitability Ratios	HOLX's Asset Turnover Ratio	HOLX's Dividend Growth
HOLX's Roe	HOLX's Valuation Ratios	HOLX's Financial Strength Ratios	HOLX's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 27 2025, within Healthcare Sector	ROA
Arrowhead Pharmaceuticals Inc	16.32 %
Vertex Pharmaceuticals Inc	16.23 %
Chemed Corporation	16.06 %
Mimedx Group Inc	15.89 %
Sbc Medical Group Holdings Incorporated	15.69 %
Indivior Pharmaceuticals Inc	15.43 %
Puma Biotechnology Inc	15.36 %
Argenx Se	14.88 %
Gilead Sciences Inc	14.82 %
Merck and Co Inc	14.64 %
Intuitive Surgical Inc	14.53 %
Strata Critical Medical Inc	14.15 %
Halozyme Therapeutics Inc	14.09 %
Black Diamond Therapeutics Inc	13.91 %
Johnson and Johnson	13.76 %
Harmony Biosciences Holdings inc	13.67 %
Illumina Inc	13.55 %
Waters Corporation	13.35 %
Keros Therapeutics Inc	13.27 %
Prestige Consumer Healthcare Inc	13.25 %
Spero Therapeutics Inc	13.04 %
Hca Healthcare Inc	12.98 %
Novartis Ag	12.59 %
Embecta Corp	12.51 %
Sab Biotherapeutics Inc	12.51 %
Carlisle Companies Incorporated	12.51 %
Aveanna Healthcare Holdings Inc	12.41 %
West Pharmaceutical Services Inc	12.38 %
Inmode Ltd	12.24 %
Dexcom Inc	11.98 %

Date modified: 2026-09-26T06:54:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.